Sector:Medtech

Year of Investment :2020年

For more information, please visit www.brattea.com


Brattea, a high-tech enterprise focusing on the development and commercialization of neuro-radiofrequency ablation technology and products, was established in 2013. Brattea has successfully deployed the treatment and management for chronic disease by developing an original transvacuolar nerve ablation technology platform. The company has a leading position in the domestic industry while surpassing international peers in the field of Renal Denervation (RDN) technology. In addition to hypertension, RDN has made great progress in tumor analgesia, diabetes, vasculitis, and atrial fibrillation.